
Researchers discover that inhibiting SREBP-dependent lipogenesis with FGH10019 enhances docetaxel’s effectiveness in prostate cancer. Blocking lipid biosynthesis shifts cell membranes toward polyunsaturated lipids, increasing drug uptake and cancer cell death. This breakthrough suggests combining lipogenesis inhibitors with chemotherapy could improve treatment outcomes
Like
Save
Share